Alternative and complementary therapy for menopausal disorders after radical treatment for breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Since 1980, breast cancer (BC) has dominated in the pattern of female cancer incidence. After successfully completing the main stage of BC treatment, patients very often survive the age at natural menopause. However, it is this form of malignant tumor that requires enormous healthcare resources to maintain the health, quality of life, and rehabilitation of women. Approximately two-thirds of BC cases are hormone-positive, i.e. they contain estrogen and/or progesterone receptors, requiring hormone (anti-estrogen) therapy. Taking hormonal drugs, such as aromatase inhibitors and tamoxifen, is associated with the development of moderate to severe menopausal disorders. To correct menopausal symptoms after completion of the main stage of BC therapy is a complex clinical task. Vasomotor symptoms can be severe and debilitating in some women, whereas menopausal hormone therapy is contraindicated. In patients with chemotherapy-induced premature menopause, loss of bone mineral density is very often accelerated and there is a need for appropriate correction. Vulvovaginal atrophy is a source of sexual dysfunction. To maintain not only somatic health and physical activity, but also to improve quality of life in patients with a family history of cancer should be the focus of clinical attention. Conclusion. The paper presents a list of alternative non-hormonal treatments for menopausal disorders in patients with a personal history of BC.

Full Text

Restricted Access

About the authors

O. V Yakushevskaya

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: ykushox83@mail.ru
Ph.D., scientific researcher of the Department of Gynecological Endocrinology 117997, Russia, Moscow, Ac. Oparina str. 4

S. V Yureneva

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
Dr. Med. Sci., Leading Researcher of the Department of Gynecological Endocrinology 117997, Russia, Moscow, Ac. Oparina str. 4

A. E Protasova

V.A. Almazov National Medical Research Center, Ministry of Health of Russia

Email: protasova1966@yandex.ru
Dr. Med. Sci., Professor of the Department of Obstetrics and Gynecology 197341, Russia, Saint Petersburg, Akkuratova str., 2

O. V Shabalova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: olga.shabalova93@gmail.com
graduent student, Department of Gynecological Endocrinology 117997, Russia, Moscow, Ac. Oparina str. 4

References

  1. Yamaguchi N., Okajima Y., Fujii T., Natori A., Kobayashi D. The efficacy of nonestrogenic therapy to hot flushes in cancer patients under hormonal manipulation therapy:a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 2013; 139(10): 101-7. https://dx.doi./10.1007/s00432-013-1491-4.
  2. Якушевская О.В. Альтернативная коррекция климактерических расстройств. Медицинский совет. 2019; 13: 131-6.
  3. Nelson H.D., Vesco K.K., Haney E., Fu R., Nedrow A., Miller J. et al. Nonhormonal therapies for menopausal hot flushes. JAMA. 2006; 295(17): 2057-71. https://dx.doi.org/10.1001/jama.295.17.2057.
  4. Einbond L.S., Wen-Cai Y, He K., Wu H.A., Cruz E., Roller M., Kronenberg F. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine. 2008; 15(6-7): 504-11. https:// dx.doi.org/10.1016/j.phymed.2007.09.017.
  5. Obi N., Chang-Claude J., Berger J., Braendle W., Slanger T., Schmidt M. et al. The use of herbals preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol. Biomarkers Prev. 2009; 18(8): 2207-13. https:// dx.doi.org/10.1158/1055-9965.EPI-09-0298.
  6. Beck V., Rohr U., Jungbauer A. Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy? J. Steroid Biochem. Mol. Biol. 2005; 94(5): 499-518. https://dx.doi.org/10.1016/j.jsbmb. 2004.12.038.
  7. Hirschberg A.L., Edlund M., Svane G., Azavedo E., Skoog L., von Schoultz B. An isopropanolic axtract of black cohosh does not increase breast density or breast cell proliferation in postmenopasal women. Menopause. 2007; 14(1): 89-96. https://dx.doi.org/10.1097/01.gme.0000230346.20992.34.
  8. Uebelhack R., Blohmer J.U., Graubaum H.J., Busch R., Gruenwald J., Wernecke K.D. Black cohosh and St John’s Wort for climacteric complaints. Obstet. Gynecol. 2006; 107(2, Pt 1): 247-55. https://dx.doi.org/10.1097/ 01.AOG.0000196504.49378.83.
  9. Shams T., Firwana B., Habib F., Alshahrani A., Alnouh B., Murad M.H., Ferwana M. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J. Gen. Intern. Med. 2014; 29(1): 204-13. https:// dx.doi.org/10.1007/s11606-013-2535-9.
  10. Orleans R.J., Li L., Kim M.J., Guo J., Sobhan M., Soule L., Joffe H.V. FDA approval of paroxetine for menopausal hotflushes. N. Engl. J. Med. 2014; 370(19): 1777-9. https://dx.doi.org/10.1056 / NEJMp1402080.
  11. Rada G., Capurro D., Pantoja T., Corbalan J., Moreno G., Letelier L.M., Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst. Rev. 2010; (9): CD004923. https:// dx.doi.org/10.1002/14651858. CD004923.pub2.
  12. Fisher W.I., Johnson A.K., Elkins G.R., Otte J.L., Burns D.S., Yu M., Carpenter J.S. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J. Clin. 2013; 63(3): 167-92. https://dx.doi.org/10.3322/ caac.21171.
  13. Grady D., Cohen B., Tice J., Kristof M., Olyaie A., Sawaya G.F. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet. Gynecol. 2007; 109(4): 823-30. https://dx.doi.org/10.1097/ 01.AOG.0000258278.73505.fa.
  14. Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H. et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305(3): 267-74. https:// dx.doi.org/10.1001/ jama.2010.2016.
  15. Desmarais J.E., Looper K.J. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J. Clin. Psychiatry. 2009; 70(12): 1688-97. https:// dx.doi.org/10.4088/JCP.08r04856blu.
  16. Santen R.J., Loprinzi C.L., Casper R.F. Menopausal hot flashes. Up to date. 2017. https://dx.doi.org/10.4065/77.11.1155.
  17. Kuhle C.L., Kapoor E., Sood R., Thielen J.M., Jatoi A., Faubion S.S. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas. 2016; 92: 86-96. https://dx.doi.org/10.1016/ j.maturitas.2016.07.018.
  18. Buijs C., Mom C.H., Willemse P.H.B., Boezen H.M., Maurer J.M., Wymenga A.N. et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind randomized cross-over study. Breast Cancer Res. Treat. 2009; 115(3): 573-80. https://dx.doi.org/10.1007/ s10549-008-0138-7.
  19. Astellas. Astellas initiates phase 3 clinical trials for fezolinetant in postmenopausal women with vasomotor symptoms. Tokyo; 6 August 2019. Available at: www. astellas.com/en/news/14866 Accessed 23 Feb 2020.
  20. Durna E.M., Wren B.G., Heller G.Z., Leader L.R., Sjoblom P., Eden J.A. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med. J. Aust. 2002; 177(7): 347-51. https://dx.doi. org/10.5694/j.1326-5377.2002.tb04835.x.
  21. Fahlen M., Fornander T., Johansson H., Johansson U., Rutqvist L.-E., Wilking N., von Schoultz E. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomized trial. Eur. J. Cancer. 2013; 49(1): 52-9. https://dx.doi.org/10.1016/j.ejca.2012.07.003.
  22. Holmberg L., Iversen O.-E., Rudenstam C.M., Hammar M., Kumpulainen E., Jaskiewicz J., Jassem J. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl. Cancer Inst. 2008; 100(7): 475-82. https://dx.doi.org/10.1093/jnci/djn058.
  23. Kenemans P., Bundred N.J., Foidart J.M., Kubista E., von Schoultz B., Sismondi P. et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double blind, randomized, non-inferiority trial. Lancet Oncol. 2009; 10(2): 135-46. https://dx.doi.org/10.1016/S1470-2045(08)70341-3.
  24. Biglia N., Gadducci A., Ponzone R., Roagna R., Sismondi P. Hormone replacement therapy in cancer survivors. Maturitas. 2004; 48(4): 333-46. https:// dx.doi.org/10.1016/j.maturitas.2003.09.031.
  25. Domchek S., Kaunitz A.M. Use of systemic hormone therapy in BRCA mutation carriers. Menopause. 2016; 23(9): 1026-7. https://dx.doi.org/10.1097/ GME.0000000000000724.
  26. Kotsopoulos J., Gronwald J., Karlan B.Y., Huzarski T., Tung N., Moller P. et al. Hormone replacement therapy after ophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018: 4(8): 1059-65. https://dx.doi. org/10.1001/jamaoncol.2018.0211.
  27. Genazzani A.R., Gaspard U., Foidart J.-M. Oral investigational drugs currently in phase I or phase II for the amelioration of menopausal symptoms. Expert Opin. Investig. Drugs. 2019; 28(3): 235-47. https://dx.doi.org/10.1080/ 13543784.2019.1572114.
  28. Gerard C., Mestdagt M, Tskitishvili E., Communal L., Compel A., Silva E. et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015; 6(19): 17621-36. https://dx.doi.org/10.18632/ oncotarget.4184.
  29. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https:// dx.doi.org/10.1097/GME.0000000000001609.
  30. Hamoda H, Davis S.R., Cano A., Morris E., Davison S., Panay N. et al. BMS, IMS, EMAS, RCOG and AMS joint statement on MHT and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. Post Reprod. Health. 2021; 27(1): 49-55. https://dx.doi.org/10.1177/2053369120983154.
  31. Leon-Ferre R.A., Novotny P.J., Wolfe E.G., Faubion S.S., Ruddy K.J., Flora D. et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 2019; 4(1): pkz088. https://dx.doi.org/10.1093/jncics/pkz088.
  32. Dew J.E., Wren B. G, Eden J.A. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003; 6(1): 45-52. https://dx.doi.org/10.1080/cmt.6.1.45.52.
  33. Wurz G.T., Soe L.H., DeGrigorio M.W. Ospemifene, vulvovaginal atrophy and breast cancer. Maturitas. 2003; 74(3): 220-5. https://dx.doi.org/10.1016/ j.maturitas. 2012.12.002.
  34. Labrie F., Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvivaginal atrophy, and of the enitourinary syndrome of menopause. Menopause. 2018; 25(11): 1339-53. https://dx.doi.org/10.1097/GME.0000000000001238.
  35. Tadir Y., Caspar A., Lev-Sagie A., Alexiades M., Alinsod R., Bader A. et al. Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversies. Lasers Surg. Med. 2017; 49(2): 137-59. https:// dx.doi.org/10.1002/lsm.22637.
  36. Стенина М.Б., Жукова Л.Г., Королева И. А., Пароконная А. А., Семиглазова Т.Ю., Тюляндин С.А., Фролова М.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. 2019; 9(3, Приложение 2): 128-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies